Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

42.70USD
24 Feb 2017
Change (% chg)

$0.19 (+0.45%)
Prev Close
$42.51
Open
$42.27
Day's High
$42.83
Day's Low
$42.26
Volume
1,786,466
Avg. Vol
2,074,165
52-wk High
$44.50
52-wk Low
$36.81

Select another date:

Fri, Feb 24 2017

BRIEF-FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi

* U.S. FTC - Approved final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Sanofi would likely be anticompetitive Source text : (http://bit.ly/2lC10ws) Further company coverage:

AARP, Eli Lilly support Sanofi, Regeneron in cholesterol drug fight

Seniors' advocacy group AARP and drugmaker Eli Lilly & Co on Thursday urged a federal appeals court to overturn a court order barring sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent.

UPDATE 2-How Sanofi lost out to J&J in $30 bln battle for Actelion

* J&J's $280 per share tender offer to start March 3 (Recasts with rival offer, adds background throughout)

BRIEF-Ipsen acquires a portfolio of select consumer healthcare products from Sanofi

* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

UPDATE 1-Drugmaker Ipsen to buy some products from Sanofi for 83 mln euros

PARIS, Feb 13 Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

BRIEF-Sanofi nearing deal to sell some over-the-counter products to Ipsen for about 100 mln euros- Bloomberg, citing source

* Sanofi nearing agreement to sell some over-the-counter products to Ipsen; deal may be announced as soon as Monday- Bloomberg, citing source

BRIEF-Regeneron posts Q4 adj. profit $3.04/shr

* Regeneron reports fourth quarter and full year 2016 financial and operating results

Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Select another date:

More From Around the Web